Oncology News | pharmaphorum

Wednesday 29 July 2026

News

News

exelixis

Exelixis doubles down on ADCs for cancer with NBE, Catalent ...

Exelixis made its name developing small-molecule drugs for cancer, so a new pair of deals focused on antibody-drug conjugates reinforces a recent change of direction for the biotech.

News

blueprint_logo

Blueprint and Roche take on Lilly as FDA approves RET-target...

Cancer drugs firm Blueprint Medicines has gained a second US approval, with its Gavreto (pralsetinib) daily pill that targets non-small cell lung cancer with RET fusion mutations.<

News

AbbVieHQ

AbbVie signs $2.9bn deal with I-Mab for ‘don’t eat me’ cance...

AbbVie has claimed rights to an immuno-oncology antibody from I-Mab in what is thought to be a record licensing deal involving a Chinese biotech.

News

cancer-t-cells-16_9

Highlight Therapeutics trials second-line melanoma combo aft...

Cancer immunotherapy has set new standards in care, with some impressive responses in those patients lucky enough to respond.

News

jounce

Gilead licenses Jounce immunotherapy for $800m

Gilead has joined forces with biotech Jounce Therapeutics to licence its immunotherapy JTX-1811 in a deal worth more than $800 million.

News

gskhouse2

GSK moves further ahead in BCMA with EU okay for Blenrep

GlaxoSmithKline has approval on both sides of the Atlantic for its multiple myeloma drug Blenrep, after getting the nod from the European Commission.